Aktienanalyse zu Verrica Pharmaceuticals Inc (VRCA)VRCAVerrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Verrica Pharmaceuticals Inc is a good buy right now due to its current price of $3.21, which is significantly below the analyst price targets of $9 and $12. The company has shown a gross margin of 85.02% in Q2 2026, indicating strong potential for profitability as it continues to develop its product YCANTH. However, the main risk is its recent performance, with a year-to-date change of -61.33%, reflecting significant volatility and financial pressure.

3 analysts cover VRCA: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 18.67.